Crinetics Pharmaceuticals, Inc. (CRNX) Financial Statements (2025 and earlier)

Company Profile

Business Address 6055 LUSK BLVD.
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,400,000558,600334,400333,700170,900118,400
Cash and cash equivalent264,54554,89732,672200,69593,08740,326
Short-term investments1,089,524503,658301,753133,01277,79378,066
Other undisclosed cash, cash equivalents, and short-term investments45,93145(25)(7)208
Restricted cash and investments      
Receivables8,3103,1411,4881,052113449
Prepaid expense1,025857939888693 
Other current assets1,2071,5782,5359121,0241,091
Other undisclosed current assets(35,154)9,9775,8228,1684,7623,399
Total current assets:1,375,388574,153345,184344,720177,492123,339
Noncurrent Assets
Operating lease, right-of-use asset43,50746,5491,4861,8922,2322,510
Property, plant and equipment12,06810,8813,5002,8253,1813,946
Restricted cash and investments8001,3001,301500500500
Other noncurrent assets2,8292,00037 4082
Other undisclosed noncurrent assets  4706681,078  
Total noncurrent assets:59,20461,2006,9926,2955,9537,038
TOTAL ASSETS:1,434,592635,353352,176351,015183,445130,377
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:21,46923,19615,3518,4685,5885,498
Accounts payable5,8536,5486,883   
Accrued liabilities8913,267694   
Other undisclosed accounts payable and accrued liabilities14,72513,3817,7748,4685,5885,498
Deferred revenue   2,200   
Debt      724
Other liabilities   1,051939835724
Other undisclosed current liabilities38,21520,7469,1216,5884,0661,394
Total current liabilities:59,68443,94227,72315,99510,4898,340
Noncurrent Liabilities
Long-term debt and lease obligation:    3,0744,0144,849
Liabilities, other than long-term debt50,10352,3058,12522349
Deferred revenue4,7044,7506,101   
Deferred compensation liability, classified    22349
Other liabilities829     
Operating lease, liability44,57047,5552,0243,0744,0144,849
Total noncurrent liabilities:50,10352,3058,1253,0764,0374,898
Total liabilities:109,78796,24735,84819,07114,52613,238
Equity
Equity, attributable to parent, including:1,324,805539,106316,328331,944168,919117,139
Common stock  253    
Accumulated other comprehensive income (loss)963977(3,931)(382)25148
Accumulated deficit(952,110)(653,702)(439,173)(275,255)(167,614)(93,802)
Other undisclosed equity, attributable to parent2,275,9521,191,578759,432607,581336,508210,793
Total equity:1,324,805539,106316,328331,944168,919117,139
TOTAL LIABILITIES AND EQUITY:1,434,592635,353352,176351,015183,445130,377

Income Statement (P&L) ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues1,0394,0134,7371,078711,193
Gain on disposition of assets for financial service operations 51  2,000  
Gross profit:1,0394,0134,7371,078711,193
Operating expenses(339,893)(226,621)(172,619)(108,780)(75,024)(55,025)
Operating loss:(338,854)(222,608)(167,882)(107,702)(74,953)(53,832)
Nonoperating income40,91613,2774,974611,1413,410
Investment income, nonoperating41,43513,4364,3171579913,460
Loss from continuing operations before equity method investments, income taxes:(297,938)(209,331)(162,908)(107,641)(73,812)(50,422)
Other undisclosed loss from continuing operations before income taxes(470)(5,198)(1,010)   
Loss from continuing operations:(298,408)(214,529)(163,918)(107,641)(73,812)(50,422)
Loss before gain (loss) on sale of properties:(107,641)(73,812)(50,422)
Net loss:(298,408)(214,529)(163,918)(107,641)(73,812)(50,422)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(298,408)(214,529)(163,918)(107,641)(73,812)(50,422)

Comprehensive Income ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(298,408)(214,529)(163,918)(107,641)(73,812)(50,422)
Other comprehensive income (loss)(14)(4,908)(3,549)(407)(123)87
Comprehensive loss:(298,422)(219,437)(167,467)(108,048)(73,935)(50,335)
Other undisclosed comprehensive income, net of tax, attributable to parent 9,816    
Comprehensive loss, net of tax, attributable to parent:(298,422)(209,621)(167,467)(108,048)(73,935)(50,335)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: